Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Irish people are more willing to get vaccines than people in many other countries, though there is a “sizeable minority” ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

One in five Irish people said they would not take a traditional vaccine, a worldwide research project found. A further one in ...

Measles, once virtually wiped out in the United States, could become commonplace again if declining vaccination rates ...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But ...

Concerned that the nation’s health leadership is casting unfounded doubt on the safety of well-studied vaccines and may take ...

The EXTRAClean Exosomal RNA Isolation Kit produces high-quality RNA that improves results from small RNA sequencing and ...

Scientists in the US say they have developed an mRNA-based vaccine that encompasses ... to have a vaccine that will give people a baseline level of immune memory to diverse flu strains, so that ...

mRNA vaccines achieved their first success against COVID-19, but could a bigger target be next? Ben Hargreaves examines whether the technology could provide a new tool against cancer, and how ...